Written Descriptions: How Much is Enough? Court Will Revisit Ariad Case to Clarify the Amount of Disclosure Necessary in Patents
February 1, 2010
Foley Partner Courtenay Brinckerhoff authored an article titled, “Written Descriptions: How Much is Enough? Court Will Revisit Ariad Case to Clarify the Amount of Disclosure Necessary in Patents” in the Genetic Engineering & Biotechnology News. Brinckerhoff discusses the Federal Circuit’s decision to rehear Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. en banc to resolve an intra-court split over whether 35 USC § 112 imposes a written-description requirement that is separate from the enablement requirement. She reviews how the outcome of the case could have significant impact on biotechnology patents, which are often vulnerable to written-description challenges.
Author(s)
Related Insights
August 14, 2025
Foley Ignite
Will the Late Summer M&A Rebound Continue into Fall?
The lazy days of summer seem to be behind us as merger and acquisition (M&A) activity is getting a jump start. A recent article in the…
August 14, 2025
Manufacturing Industry Advisor
Tariffs and Your Contracts: Why do delivery terms matter?
In light of a trade landscape rife with tariffs, companies are examining their commercial contracts to judge the exposure to increased costs of production. One area of a supply contract that cannot be overlooked when determining this type of exposure is the delivery terms for the product sale. This is because the delivery terms of a contract may identify the party responsible for payment of tariffs.
August 14, 2025
Foley Viewpoints
SEC Intensifies Scrutiny of Chief Compliance Officers
Two recent SEC enforcement actions serve as a sharp reminder that Chief Compliance Officers (CCOs) can face personal liability for what…